This record was last updated December 18, 2024 (before its estimated April 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
PM8002 is a bispecific antibody targeting PD-L1 and VEGF. This study will evaluate the efficacy and safety of PM8002 in combination with paclitaxel as second line treatment for SCLC.
Protocol Amendment History
1 amendment
This ClinicalTrials.gov record has been amended once since 2023-05-25.
Status change: Recruiting → Active, Not Recruiting2024-12-15